Studies may not reflect ‘real-world experience,’ says Dr. Haluk Aydin Topaloglu

There have been no meta-analysis in SMA (Spinal Muscular Atrophy) treatments, which has led to a significant disability that is rather new to yield concrete results, the Turkish pediatrician told.

"It is early to have a concrete conclusion. Actually, there may never be a conclusion or it may take a couple of years more to have an idea. However, all these treatment modalities (they are all molecular with different configurations) seem to be working," Prof. Dr. Haluk Aydın Topaloğlu from Yeditepe University Hospitals in Istanbul.

There are three ongoing studies, including Nusinersen, Gene Therapy and Risdiplam, said Prof. Dr. Haluk Aydın Topaloğlu. "So far, about 10,000 patients have received this molecule worldwide, while in Turkey, at least 650 patients are under current treatment with Nusinersen."

The first drug to treat SMA, Nusinersen, which was approved by the US Food and Drug Administration (FDA) in 2016, is widely used in almost all developed countries and larger data is being accumulated. Another method is gene therapy, which is currently conducted in several European countries along with Japan, Australia and the US.

"Risdiplam study, which is under search and development, is also similarly active and widespread, including Turkey. There are two Turkish children that I personally follow at my institute in Istanbul" he said.

The efficacy of experimental drugs and treatments for SMA has not yet been fully proven.

Touching on SMA studies with patients, the pediatrician said studies are done in a limited number of cases. That also applies to other rare genetic disorders.

"I do not think there will be augmentation in the number of babies recruited, because initial studies are always done on selected patients and age groups only to match with the demands of the statisticians to keep the data influx minimum required" said Prof. Dr. Haluk Aydın Topaloğlu.

 

He Stressed that Clinical Trials May not Represent a Real-World Experience.

"I can give an example of the COVID-19 vaccines. Study cases were limited but now they have received worldwide appreciation. What we know for SMA is that all the time patients in the study arm have significantly better results than the placebo groups. This is a positive observation, and has led health authorities globally for approval" he said.

Commenting on the process of the development of the drug, he said first, developing the candidate molecule takes around 15 years. This is followed by a combined effort to test in clinical trials the form of phase I, II and III in a cumulative manner. All these are preceded by animal studies before any use or trial in humans.

On recommendations for families with SMA patients, he said the most essential issue in the treatments is that they should be initiated as early as possible, such as before 3 months old in SMA I - severe type. Otherwise benefit will probably be limited.

"All the treatment modalities at hand should be considered as disease-modifying agents” he said, adding that at an ordinary level, the efficacy of the drug differs among patients.

"The general health of the child such as nutrition, bone health, pulmonary, cardiac, etc. should be monitored accordingly" he said.

Whether you live in Istanbul, across Turkey or around world, specialists at Yeditepe University Healthcare Institutions are available to review your medical records and provide an expert opinion on your diagnosis or treatment plan -without the need for an in- person visit.

Yeditepe University Healthcare Institutions collaborates with digital platforms via tele-medicine, to offer remote second opinions from Yeditepe University Healthcare Institutions in virtually every medical specialty. Having a second opinion can reassure you about a challenging diagnosis, or help you and your doctor plan the most appropriate course of treatment.

To have a medical second opinion, click here and complete the online form or call us on 009 0216 578 4 578

Making an appointmet at Yeditepe University Healthcare Institutions couldn't be easier, wheter you use your private medical insurance, pay for your own treatment ora re funded by third party.

As one of the region's leading independent private hospitals, we offer appointments with World class specialist and experts.

As an international patient, you will be you will be offered comprehensive service in the language of your choice right from your initial enquiry, through your medical treatment and, if necessary, help in liaising with your doctor in your home country upon your return home.

To book an appointment, click here and complete the online form or call us on 009 0216 578 4 578

Plese click here for Frequently Asked Questions regarding Yeditepe University Healthcare Institutions